Japan incorporates risk-based approaches into drug quality audits by prioritizing inspections based on potential risks to public health. This involves evaluating manufacturers’ compliance history, product types, and manufacturing processes. Advanced data analytics and continuous monitoring help identify high-risk areas, ensuring resources focus on critical issues to enhance drug safety and quality.